GlaxoSmithKline Pharmaceuticals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 16, 2026
- Posted by: Harsh Piplani
- Category: Results
GLAXO share price Rs 2,838.80 on 16 September 2026, up 0.71%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 237.00 crore. Q2 FY26 base a profit of Rs 257.00 crore.
Quick Answer
The GlaxoSmithKline Pharmaceuticals Q2 results date for FY27 is not confirmed, and GlaxoSmithKline Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 980.00 crore in revenue and a profit of Rs 257.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The GlaxoSmithKline Pharmaceuticals Q2 results FY27 announcement is the next scheduled earnings event for GlaxoSmithKline Pharmaceuticals Ltd., GlaxoSmithKline Pharmaceuticals develops and markets prescription medicines and vaccines in India as the local pharmaceutical arm of GSK.. The stock traded at Rs 2,838.80 on the NSE on 16 September 2026, up 0.71% from the previous close of Rs 2,818.90, about 9.0% below its 52-week high of Rs 3,120.70 and 36.0% above its 52-week low of Rs 2,088.10.
What makes the GlaxoSmithKline Pharmaceuticals Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 980.00 crore of revenue and a profit of Rs 257.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 938.00 crore and a profit of Rs 237.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the GlaxoSmithKline Pharmaceuticals Q2 Results FY27 Date?
The GlaxoSmithKline Pharmaceuticals Q2 results date for FY27 is not confirmed. As of 16 September 2026, GlaxoSmithKline Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the GlaxoSmithKline Pharmaceuticals Q2 results date becomes public through that filing rather than through any advance announcement.
The GlaxoSmithKline Pharmaceuticals Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for GlaxoSmithKline Pharmaceuticals.
GlaxoSmithKline Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the GlaxoSmithKline Pharmaceuticals Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for GlaxoSmithKline Pharmaceuticals. The GlaxoSmithKline Pharmaceuticals Q2 results watchlist below is built from what the company has actually reported and disclosed.
GlaxoSmithKline Pharmaceuticals Q2 results for the September 2026 quarter follow a period in which revenue climbed to a peak before easing over the two most recent quarters. Sales rose from Rs 805 crore in June 2025 to Rs 980 crore in September 2025 and a period high of Rs 1,041 crore in December 2025, before softening to Rs 995 crore in March 2026 and Rs 938 crore in June 2026. Ahead of GlaxoSmithKline Pharmaceuticals Q2 results, this pattern of a December 2025 peak followed by two quarters of moderation is consistent with normal seasonal softness for the business rather than any flagged anomaly. GlaxoSmithKline Pharmaceuticals Q2 results for the September 2026 quarter will be watched to see whether revenue stabilizes near the June 2026 level of Rs 938 crore or continues the gradual pullback seen since the December 2025 high.
Operating margin at GlaxoSmithKline Pharmaceuticals moved from 31 percent in June 2025 to 34 percent in September 2025 and a peak of 36 percent in December 2025, before easing to 35 percent in March 2026 and 31 percent in June 2026. Net profit followed the same arc, rising from Rs 205 crore in June 2025 to Rs 257 crore in September 2025 and a high of Rs 296 crore in December 2025, then declining to Rs 278 crore in March 2026 and Rs 237 crore in June 2026. Ahead of GlaxoSmithKline Pharmaceuticals Q2 results for the September 2026 quarter, both margin and net profit have eased from their December 2025 peak in step with the revenue moderation, without any loss-making quarter or one-off item disrupting the pattern. GlaxoSmithKline Pharmaceuticals Q2 results will indicate whether this gradual easing from the December 2025 peak has run its course.
GlaxoSmithKline Pharmaceuticals trades at a price to earnings multiple of about 45.5, with book value near Rs 134 per share, a high return on equity of roughly 45.6 percent, return on capital employed near 61.4 percent and a dividend yield of about 2.02 percent, reflecting the asset-light, near debt-free profile of the business. The main context to carry into GlaxoSmithKline Pharmaceuticals Q2 results for the September 2026 quarter is that the softer March and June 2026 numbers reflect normal seasonal softness after the December 2025 peak rather than any flagged one-off item or data-quality concern in the underlying financials. With no loss-making quarter, negative net worth, or unusual income item across the period, GlaxoSmithKline Pharmaceuticals Q2 results carry a comparatively clean historical base, and GlaxoSmithKline Pharmaceuticals Q2 results should be read mainly through the lens of this seasonal moderation.
Check GlaxoSmithKline Pharmaceuticals Ltd. Live Fundamentals on the Univest Screener
GlaxoSmithKline Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On
GlaxoSmithKline Pharmaceuticals Ltd. reported revenue of Rs 938.00 crore in Q1 FY27, up 16.52% from Rs 805.00 crore in Q1 FY26, and a profit of Rs 237.00 crore at the net level, up 15.61% from Rs 205.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was down 5.73% over the March 2026 quarter figure of Rs 995.00 crore, and net profit was down 14.75% from Rs 278.00 crore in Q4 FY26. Operating margin stood at 31.0% in Q1 FY27 against 34.0% in the September 2025 quarter, which is the comparison the GlaxoSmithKline Pharmaceuticals Q2 results print will be read against.
Q2 FY26 Base: The Comparison GlaxoSmithKline Pharmaceuticals Q2 Results FY27 Must Beat
GlaxoSmithKline Pharmaceuticals Ltd. reported revenue of Rs 980.00 crore and a profit of Rs 257.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this GlaxoSmithKline Pharmaceuticals Q2 results preview.
Net profit in that base quarter was above the Rs 237.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a demanding level. Revenue of Rs 980.00 crore sits above the Rs 938.00 crore of the June 2026 quarter, which frames how much sequential movement the GlaxoSmithKline Pharmaceuticals Q2 results print needs to show growth.
GlaxoSmithKline Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 980.00 | 257.00 |
| Q3 FY26 (Dec 2025) | 1,041.00 | 296.00 |
| Q4 FY26 (Mar 2026) | 995.00 | 278.00 |
| Q1 FY27 (Jun 2026) | 938.00 | 237.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this GlaxoSmithKline Pharmaceuticals Q2 results preview uses.
Revenue across those four quarters ranged from Rs 938.00 crore to Rs 1,041.00 crore, and net profit from Rs 237.00 crore to Rs 296.00 crore. That spread is the honest context for the GlaxoSmithKline Pharmaceuticals Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape GlaxoSmithKline Pharmaceuticals Q2 Results FY27
The GlaxoSmithKline Pharmaceuticals Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what GlaxoSmithKline Pharmaceuticals has already reported.
Valuation Snapshot
GlaxoSmithKline Pharmaceuticals trades at a price to earnings ratio of about 45.67 against trailing earnings per share of Rs 62.15, with the stock priced near Rs 2,838.8. Book value stands around Rs 134 per share, putting the price to book ratio at a high 21.19, reflecting the company’s asset-light structure. Return on equity is a strong 45.6 percent, underscoring efficient capital use typical of an MNC pharmaceutical business, while the dividend yield of about 2.02 percent adds a steady income component alongside the premium valuation multiples the stock currently commands.
Technical and Price Context
GlaxoSmithKline Pharmaceuticals shares trade around Rs 2,838.8, below the 52-week high of Rs 3,120.7 but well above the 52-week low of Rs 2,088.1, keeping the stock in the upper half of its annual range. The stock trades above both its 50-day moving average of Rs 2,563.75 and its 200-day moving average of Rs 2,579.26, pointing to a sustained uptrend relative to its medium and longer-term trend lines. The relative strength index of 27.2 is in oversold territory, suggesting a recent pullback within an otherwise firm longer-term trend.
Balance Sheet and Payout
GlaxoSmithKline Pharmaceuticals carries a debt to equity ratio of just 0.01, effectively operating debt free, which is described by the screener as typical of an asset-light pharma MNC with very high return on equity and return on capital employed. This near-zero borrowing base means interest costs have negligible impact on reported profit across the recent quarters. The dividend yield of about 2.02 percent reflects a policy of returning a steady share of profit to shareholders each year, supported by the company’s strong and consistent cash generation rather than any external financing.
GlaxoSmithKline Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print
GlaxoSmithKline Pharmaceuticals share price today is Rs 2,838.80 on the NSE, up Rs 19.90 or 0.71% from the previous close of Rs 2,818.90 on 16 September 2026, ahead of the GlaxoSmithKline Pharmaceuticals Q2 results announcement.
| Metric | Value (16 September 2026) |
|---|---|
| NSE Symbol | GLAXO |
| Current Market Price | Rs 2,838.80 |
| 52-Week High | Rs 3,120.70 |
| 52-Week Low | Rs 2,088.10 |
| Market Capitalisation | Rs 48098 crore |
| PE Ratio | 45.67 |
| PB Ratio | 21.19 |
| EPS (TTM) | Rs 62.15 |
| Book Value per Share | Rs 134.00 |
| Debt to Equity | 0.01 |
| Return on Equity | 45.6% |
| 50-Day Moving Average | Rs 2563.75 |
| 200-Day Moving Average | Rs 2579.26 |
| RSI (14) | 27.20 |
The stock trades above both its 50-day average of Rs 2563.75 and its 200-day average of Rs 2579.26, with a 14-day RSI of 27.20. None of this is a view on where the shares go once the GlaxoSmithKline Pharmaceuticals Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track GlaxoSmithKline Pharmaceuticals Ltd. live price and quarterly earnings updates.
What Investors Should Watch When GlaxoSmithKline Pharmaceuticals Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the GlaxoSmithKline Pharmaceuticals Q2 results print in proportion.
- Revenue against the Rs 980.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 257.00 crore in that same quarter
- Operating margin against 31.0% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the GlaxoSmithKline Pharmaceuticals Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on GlaxoSmithKline Pharmaceuticals Q2 Results FY27
The GlaxoSmithKline Pharmaceuticals Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. GlaxoSmithKline Pharmaceuticals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the GlaxoSmithKline Pharmaceuticals Q2 results FY27 print faces a base of Rs 980.00 crore in revenue and a profit of Rs 257.00 crore, with the most recent quarter having delivered Rs 938.00 crore and a profit of Rs 237.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for GlaxoSmithKline Pharmaceuticals, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on GlaxoSmithKline Pharmaceuticals Q2 Results FY27
What is the GlaxoSmithKline Pharmaceuticals Q2 results date for FY27?
Ans. The GlaxoSmithKline Pharmaceuticals Q2 results date for FY27 is not confirmed. GlaxoSmithKline Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the GlaxoSmithKline Pharmaceuticals Q2 results 2026 cover?
Ans. The GlaxoSmithKline Pharmaceuticals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. GlaxoSmithKline Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the GlaxoSmithKline Pharmaceuticals Q2 results filing also carries the notes to the accounts.
What were the GlaxoSmithKline Pharmaceuticals Q1 FY27 results?
Ans. GlaxoSmithKline Pharmaceuticals Ltd. reported revenue of Rs 938.00 crore in Q1 FY27 and a profit of Rs 237.00 crore at the net level. Revenue was up 16.52% versus Q1 FY26 and net profit was up 15.61% from Rs 205.00 crore in Q1 FY26.
What were GlaxoSmithKline Pharmaceuticals Q2 FY26 results in the September 2025 quarter?
Ans. GlaxoSmithKline Pharmaceuticals Ltd. reported revenue of Rs 980.00 crore and a profit of Rs 257.00 crore in Q2 FY26. Operating margin was 34.0%. Those figures form the base for the GlaxoSmithKline Pharmaceuticals Q2 results FY27 comparison.
What are the main GlaxoSmithKline Pharmaceuticals Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The GlaxoSmithKline Pharmaceuticals Q2 results expectations centre on revenue against the Rs 980.00 crore base, net profit against a profit of Rs 257.00 crore, operating margin against 31.0% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is GlaxoSmithKline Pharmaceuticals share price today ahead of the Q2 earnings?
Ans. GlaxoSmithKline Pharmaceuticals share price is Rs 2,838.80 on the NSE as of 16 September 2026, up 0.71% from Rs 2,818.90. The stock is about 9.0% below its 52-week high of Rs 3,120.70 and 36.0% above its 52-week low of Rs 2,088.10, at a market capitalisation of Rs 48098 crore.
Is GlaxoSmithKline Pharmaceuticals a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on GlaxoSmithKline Pharmaceuticals Ltd. The stock trades at a price-to-book ratio of 21.19 with a return on equity of 45.6%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
